current-topics-in-peptide---protein-research-impact-factor The CT38 peptide is an experimental therapeutic agent currently under investigation for its potential to treat a range of chronic neurological and systemic conditions. Developed by Cortene Inc., CT38 is a proprietary 40-amino acid peptide designed to act as a selective agonist for the corticotropin-releasing factor receptor type 2 (CRFR2).September Message: Cortene Study Published This mechanism of action is central to its proposed therapeutic benefits, particularly in conditions where dysregulation of the CRFR2 pathway is believed to play a role.Peptides for pain sensation and peptides for pain relief: Fighting fire ... Early research and clinical trials have focused on its safety, tolerability, and efficacy, with promising preliminary results in specific patient populations.
CT38 functions by stimulating the CRFR2 receptor. This receptor is part of the broader corticotropin-releasing factor (CRF) system, which is involved in the body's response to stress and inflammation. By selectively activating CRFR2, CT38 aims to modulate inflammatory pathways and potentially restore balance in systems affected by chronic disease.KLH conjugated synthetic peptide derived from human FTHL17/CT38(1-100/183aa). Target, FTHL17. Purification, Affinity purified by Protein A. Conjugation, PE/Cy7 ... The peptide is composed entirely of naturally occurring amino acids, a characteristic that contributes to its safety profile.
Cortene Inc.2021年9月12日—CT38 is a peptide with a half-life of 1.5 hoursand patients in the trial only got infusions for 2-3 days. So even though the impact of the ... has been actively developing CT38 for several years. Initial studies, including Phase 1 trials, have established that CT38 is safe and well-tolerated when administered, typically via subcutaneous infusion2018年3月16日—The Drug –CT38. Cortene's drug, CT38, is a CRF2 agonist, i.e., it stimulates CRF2. It is comprised only of amino acids that occur naturally .... The peptide has a relatively short half-life of approximately 1.5 hours, and treatment regimens have often involved short infusion periods.Effect of CT38 in healthy subjects (triangles, green line)... This targeted approach aims to deliver therapeutic effects while minimizing systemic exposure. The company's pipeline indicates readiness for Phase 2 clinical trials, exploring CT38's utility in conditions like Parkinson's and Alzheimer's diseases, building upon earlier investigations.
The primary focus of CT38 research has been its potential application in treating debilitating chronic conditions. Notably, CT38 has been investigated in clinical trials for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).2021年9月2日—CT38was subcutaneously infused at one of four infusion rates for a maximum of 10.5 hours, in 14 ME/CFS patients.CT38treatment was safe and ... Preliminary findings from these trials have suggested that CT38 treatment was safe and validated the hypothesis that the CRFR2 receptor is involved in ME/CFS.
Beyond ME/CFS, CT38 is also being studied for its effects in fibromyalgia and chronic Lyme disease2018年3月16日—The Drug –CT38. Cortene's drug, CT38, is a CRF2 agonist, i.e., it stimulates CRF2. It is comprised only of amino acids that occur naturally .... The broader implications of CT38's mechanism extend to other "brain-centric acquired chronic diseases," as Cortene describes them. Furthermore, there is interest in testing CT38 for Long Covid, the post-acute stage of COVID-19 infection, given its potential to address chronic inflammatory and neurological sequelae.
Clinical trials to date have generally reported CT38 to be safe and tolerable for patients2018年3月16日—The Drug –CT38. Cortene's drug, CT38, is a CRF2 agonist, i.e., it stimulates CRF2. It is comprised only of amino acids that occur naturally .... The focus remains on further evaluating its efficacy across a range of indications. The development of CT38 represents a significant effort in exploring novel peptide-based therapeutics for complex chronic illnesses. As research progresses through further clinical phases, the full therapeutic potential of this experimental peptide will become clearer, offering hope for new treatment avenues for patients suffering from these challenging conditions.RECOVER-TLC Therapeutics
Join the newsletter to receive news, updates, new products and freebies in your inbox.